Abstract Since the first application of whole brain radiation therapy (WBRT) to brain metastases in 1950 s,it has been regarded as a standard treatment for brain metastases of non-small cell lung cancer (NSCLC).Recently, more accurate radiotherapy technique and more effective systemic therapy have been developed. Especially, the molecular targeted drugs are upgraded rapidly with stronger targeting capability and better permeability of the central nervous system. With the prolonged survival of patients, long-term damage to the nervous system induced by WBRT causes widespread concerns. This article will review the related controversies and research progress in the application of WBRT to NSCLC with brain metastases in modern integrated therapy.
Fund:Jilin Provincial Development and Reform Commission (2016C053-1);Jilin Provincial Science and Technology Department (201603040YY)
Corresponding Authors:
Liu Min,Email:liumin602822@163.com;Dong Lihua,Email:drlhdong@163.com
Cite this article:
Lv Jincai,Liu Bailong,Quan Xiaoyue et al. Research progress in radiotherapy for brain metastases of non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(1): 61-64.
Lv Jincai,Liu Bailong,Quan Xiaoyue et al. Research progress in radiotherapy for brain metastases of non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(1): 61-64.
[1] Govindan R,Page N,Morgensztern D,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J].J Clin Oncol,2006,24(28):4539-4544.DOI:10.1200/JCO.2005.04.4859. [2] Chao JH,Phillips R,Nickson JJ.Roentgen-ray therapy of cerebral metastases[J].Cancer,1954(7):682-689.DOI:10.1002/1097-0142(195407)7:4<682::AID-CNCR2820070409>3.0.CO;2-S. [3] Magnuson WJ,Lester-Coll NH,Wu AJ,et al. Management of brain metastases in tyrosine kinase inhibitor-native epidermal growth factor receptor-mutant non-small-cell lung cancer:a retrospective multi-institutional analysis[J].J Clin Oncol,2017,35(10):1070.DOI:10.1200/JCO.2016.69.7144. [4] Aoyama H,Shirato H,Tago M,et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases:a randomized controlled trial[J].JAMA,2006,295(21):2483-2491.DOI:10.1001/jama.295.21.2483. [5] Chang EL,Wefel JS,Hess KR,et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation:a randomised controlled trial[J].Lancet Oncol,2009, 10(11):1037-1044.DOI:10.1016/S1470-2045(09)70263-3. [6] Kocher M,Soffietti R,Abacioglu U,et al. Adjuvant whole-brain radiotherapy vs. observation after radiosurgery or surgical resection of 1 to 3 cerebral metastases:results of the EORTC 22952-26001 study[J].J Clin Oncol,2011,29(2):134-141.DOI:10.1200/JCO.2010.30.1655. [7] Brown PD,Jaeckle K,Ballman KV,et al. Effect of radiosurgery alone vs. radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases:a randomized clinical trial[J].JAMA,2016,316(4):401-409.DOI:10.1001/jama.2016.9839. [8] Aupérin A,Arriagada R,Pignon JP,et al,Prophylactic cranial irradiation overview collaborative group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission[J].N Engl J Med,1999,341(7):476-484.DOI:10.1056/NEJM199908123410703. [9] Pirzkall A,Debus J,Lohr F,et al. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases[J].J Clin Oncol,1998,16(11):3563-3569.DOI:10.1200/JCO.1998.16.11.3563. [10] Aoyama H,Tago M,Shirato H,Japanese Radiation Oncology Study Group 99-1(JROSG99-1) Investigators. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases:secondary analysis of the JROSG 99-1 randomized clinical trial[J].JAMA Oncol,2015,1(4):457-464.DOI:10.1001/jamaoncol.2015.1145. [11] Johung KL,Yeh N,Desai NB,et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis[J].J Clin Oncol,2016,34(1):123-129.DOI:10.1200/JCO.2015.62.0138. [12] Onodera S,Aoyama H,Tha KK,et al. The value of 4-month neurocognitive function as an endpoint in brain metastases trials[J].J Neurooncol,2014,120(2):311-9.DOI:10.1007/s11060-014-1550-y. [13] McDuff SG,Taich ZJ,Lawson JD,et al. Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases[J].J Neurol Neurosurg Psychiat,2013,84(12):1384-1391.DOI:10.1136/jnnp-2013-305166. [14] Mehta MP,Aoyama H,Gondi V.The changing role of whole-brain radiotherapy[J].JAMA Oncol,2017,3(1):1-2.DOI:10.1001/jamaoncol.2016.5414. [15] Gondi V,Pugh SL,Tome WA,et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933):a phase Ⅱ multi-institutional trial[J].J Clin Oncol,2014,32(34):3810-3806.DOI:10.1200/JCO.2014.57.2909. [16] Rapp SR,Case LD,Peiffer A,et al. Donepezil for irradiated brain tumor survivors:a phase Ⅲ randomized placebo-controlled clinicaltrial[J].J Clin Oncol,2015,33(15):1653-1659.DOI:10.1200/JCO.2014.58.4508. [17] Brown PD,Pugh S,Laack NN,et al. Radiation Therapy Oncology Group. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy:a randomized,double-blind,placebo-controlled trial[J].Neuro Oncol,2013,15(10):1429-1437.DOI:10.1093/neuonc/not114. [18] Soon YY,Leong CN,Koh WY,et al. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases:a systematic review and meta-analysis[J].Radiother Oncol,2015,114(2):167-172.DOI:10.1016/j.radonc.2014.12.011. [19] Costa DB,Shaw AT,Ou SH,et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases[J].J Clin Oncol,2015,33(17):1881-1888.DOI:10.1200/JCO.2014.59.0539. [20] Yamamoto M,Ide M,Nishio S,Urakawa Y.Gamma knife radiosurgery for numerous brain metastases:is this a safe treatment?[J].Int J Radiat Oncol Biol Phys,2002,53(5):1279-1283.DOI:org/10.1016/S0360-3016(02)02855-9. [21] Yamamoto M,Barfod BE,Urakawa Y.Gamma knife radiosurgery for brain metastases of non-lung cancer origin:focusing on multiple brain lesions[J].Prog Neurol Surg,2009,22(2):154-169.DOI:10.1159/000163413. [22] Yamamoto M,Kawabe T,Higuchi Y,et al. Delayed complications in patients surviving at least 3 years after stereotactic radiosurgery for brain metastases[J].Int J Radiat Oncol Biol Phys,2013,85(1):53-60.DOI:10.1016/j.ijrobp.2012.04.018. [23] Yamamoto M,Serizawa T,Shuto T,et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901):Amulti-institutional prospective Observational study[J].Lancet Oncol,2014,15(4):387-395.DOI:10.1016/S1470-2045(14)70061-0. [24] Yamamoto M,Serizawa T,Higuchi Y,et al. A Multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901 study update):irradiation-related complications and long-term maintenance of mini-mental state examination scores[J].Int J Radiat Oncol Biol Phys,2017,99(1):31-40.DOI:10.1016/j.ijrobp.2017.04.037. [25] Nabors LB,Portnow J,Ammirati M,et al. Central nervous system cancers,version 1.2015[J].J Nat Compre Cancer Network J NCCN,2015,13(10):1191.DOI:10.6004/jnccn.2015.0148. [26] Barlesi F,Mazieres J,Merlio JP,et al. Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer:results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)[J].Lancet,2016,387(10026):1415-1426.DOI:10.1016/S0140-6736(16)00004-0. [27] Sperduto PW,Yang TJ,Beal K,et al. Estimating survival in patients with lung cancer and brain metastases:an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA)[J].JAMA Oncol,2017,3(6):827-831.DOI:10.1001/jamaoncol.2016.3834. [28] Yang JJ,Zhou C,Huang Y,et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN):a multicentre,phase 3,open-label,parallel,randomised controlled trial[J].Lancet Respir Med,2017,5(9):707-716.DOI:10.1016/S2213-2600(17)30262-X. [29] Zimmermann S,Dziadziuszko R,Peters S.Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases[J].Cancer Treat Rev,2014,40(6):716-722.DOI:10.1016/j.ctrv.2014.03.005.
2019, Vol. 28 
